Genflow Biosciences Plc (DE:WQ5)
FRANKFURT:WQ5
WQ5 Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EST
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)833.00
Market Cap
€13.91M
Enterprise Value€11.33M
Total Cash (Recent Filing)€279.44K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding566,409,800
10 Day Avg. Volume2,500
30 Day Avg. Volume833
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial DebtHaving zero financial debt materially reduces refinancing and interest burden risk for a pre-revenue biotech. This strengthens strategic flexibility for R&D financing, partnership timing and clinical program pacing, lowering bankruptcy risk and preserving cash for critical development milestones.
Aging-focused Gene Therapy Franchise (structural Tailwind)The firm’s focus on ageing and sirtuin-related gene approaches targets a large, structural market driven by demographic ageing and chronic disease prevalence. High unmet need and scientific specialization create durable market opportunity and high entry barriers for competitors if programs translate clinically.
Improving Cash Flow And Loss Trajectory In 2025An improvement in free cash flow and modestly smaller net losses in 2025 indicate operational progress versus prior year. For a clinical-stage biotech, a narrowing loss trend can extend runway, reduce immediate dilution pressure and suggest better cost discipline or program prioritization over the medium term.
Bears Say
Pre-revenue With Persistent Operating Losses And Negative EquityBeing pre-revenue with sustained operating losses and a slide to negative shareholders’ equity is a critical structural weakness. It signals accumulated deficits that constrain strategic options, increase insolvency risk under stress and heighten reliance on external capital to execute long-duration clinical programs.
Chronic Negative Cash Generation; Dependent On External FundingConsistent multi-year cash burn means the company cannot self-fund development and must repeatedly access markets or partners. This creates durable dilution and execution risk, complicates long-term planning for expensive trials, and can force unfavorable financing or hurried partnerships under adverse conditions.
Modest Asset Base Limits Balance-sheet FlexibilityA small asset base reduces collateral and negotiating leverage for licensing, debt or strategic collaborations. For a biotech needing capital for clinical stages, limited assets constrain alternative funding routes, increase dependence on equity raises and weaken resilience to trial setbacks or regulatory delays.
Genflow Biosciences Plc News
WQ5 FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is €13.91M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 111 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 566,409,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in DE:WQ5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---